We are live on ! Find out more
PIM

Partner Investment Management Portfolio holdings

AUM $13.9M
1-Year Est. Return 55.92%
This Fund
S&P 500
This Quarter Est. Return
-4.98%
1 Year Est. Return
+55.92%
3 Year Est. Return
+168.07%
5 Year Est. Return
+301.91%
10 Year Est. Return
–
AUM
$66.2M
AUM Growth
-$4.96M
Cap. Flow
+$13.4M
Cap. Flow %
20.26%
Top 10 Hldgs %
43.96%
Holding
112
New
26
Increased
20
Reduced
20
Closed
42

Top Buys

Rank Stock Value
1
AGN
Allergan plc
AGN
+$3.62M
2
PFE icon
Pfizer
PFE
+$3.09M
3
GILD icon
Gilead Sciences
GILD
+$2.52M
4
UNH icon
UnitedHealth
UNH
+$2.44M
5
LLY icon
Eli Lilly
LLY
+$1.85M

Top Sells

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$1.61M
2
THC icon
Tenet Healthcare
THC
+$1.3M
3
AAPL icon
Apple
AAPL
+$1.26M
4
BRCM
BROADCOM CORP CL-A
BRCM
+$1.13M
5
LBTYK icon
Liberty Global Class C
LBTYK
+$1.13M

Sector Composition

Rank Sector Weight
1 Healthcare 61.28%
2 Communication Services 5.62%
3 Financials 5.54%
4 Technology 4.38%
5 Consumer Discretionary 4.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZLTQ
51
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
$337K 0.51%
+10,519
New +$348K
TXT icon
52
Textron
TXT
$15.4B
$222K 0.34%
+5,899
New +$244K
DBVT
53
DBV Technologies
DBVT
$847M
$220K 0.33%
+620
New +$244K
ADAP
54
DELISTED
Adaptimmune Therapeutics
ADAP
$218K 0.33%
18,194
– –
BPMC
55
DELISTED
Blueprint Medicines
BPMC
$217K 0.33%
10,154
+2,804
+38% +$77.6K
HDP
56
DELISTED
Hortonworks, Inc.
HDP
$208K 0.31%
9,510
-4,409
-32% -$109K
CHRS icon
57
Coherus Oncology
CHRS
$196M
$141K 0.21%
7,031
– –
FOMX
58
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$80K 0.12%
10,893
– –
RGNX icon
59
Regenxbio
RGNX
$708M
$54K 0.08%
+2,466
New +$62.9K
AGN
60
CALL
DELISTED
Allergan plc
AGN
$53K 0.08%
+6,600
New +$2.03M
MRK icon
61
PUT
Merck
MRK
$318B
$31K 0.05%
+24,418
New +$1.3M
PTCT icon
62
CALL
PTC Therapeutics
PTCT
$6.12B
$30K 0.05%
+9,900
New +$423K
TEVA icon
63
CALL
Teva Pharmaceuticals
TEVA
$41.2B
$20K 0.03%
+53,000
New +$3.44M
MXL icon
64
MaxLinear
MXL
$6.8B
$16K 0.02%
1,314
-1,703
-56% -$18.8K
KERX
65
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$8K 0.01%
+2,313
New +$15.5K
BMY icon
66
CALL
Bristol-Myers Squibb
BMY
$132B
$7K 0.01%
+45,100
New +$2.86M
PFE icon
67
CALL
Pfizer
PFE
$153B
$6K 0.01%
+52,278
New +$1.68M
MCK icon
68
CALL
McKesson
MCK
$101B
$1K ﹤0.01%
+6,900
New +$1.46M
ROK icon
69
CALL
Rockwell Automation
ROK
$49B
$1K ﹤0.01%
+6,400
New +$725K
AAPL icon
70
CALL
Apple
AAPL
$4.57T
– –
-35,600
Closed -$5K
AAPL icon
71
Apple
AAPL
$4.57T
– –
-40,292
Closed -$1.26M
ACHC icon
72
Acadia Healthcare
ACHC
$2.94B
– –
-5,563
Closed -$436K
BHC icon
73
Bausch Health
BHC
$2.34B
– –
-4,412
Closed -$980K
BIDU icon
74
Baidu
BIDU
$37.2B
– –
-4,710
Closed -$938K
BLUE
75
DELISTED
bluebird bio
BLUE
– –
-221
Closed -$482K
1 2
3
4 5

Similar funds

SWM
Sequoia Wealth Management Hoffman Estates, Illinois $12.9M AUM 25.75% 1-Year Est. Return
ACM
ADI Capital Management New York $17.5M AUM 49.32% 1-Year Est. Return
ECAU
Everett Capital Advisors (UK) London, United Kingdom $18.6M AUM 22.81% 1-Year Est. Return
SL
Signition LP New York $20M AUM 28.26% 1-Year Est. Return
DII
Domini Impact Investments New York $7.59M AUM 47.68% 1-Year Est. Return
FIM
FourPoints Investment Managers Paris, France $21.1M AUM 11.11% 1-Year Est. Return
EM
Emancipation Management New York $22.4M AUM 18.33% 1-Year Est. Return
BHC
Balch Hill Capital San Francisco, California $22.8M AUM

Partner Investment Management's Q3 2015 Portfolio in Review

As of Q3 2015, Partner Investment Management held 112 positions worth $66.2M, down 7% from $71.1M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Partner Investment Management deployed $13.4M of net new capital in Q3 2015, opening 26 new positions and adding to 20 existing holdings. Its largest new stake was Allergan plc: 11,785 shares worth $3.2M.

By sector, the portfolio is most concentrated in Healthcare at 61% of assets, up from 50% a quarter earlier, followed by Communication Services and Financials.

On the sell side, the largest reduction was BROADCOM CORP CL-A, an estimated $1.13M trimmed.

  • Partner Investment Management's largest Q3 2015 buy was Allergan plc: 11,785 shares worth $3.2M.
  • Partner Investment Management added most to UnitedHealth in Q3 2015, an estimated $2.44M increase.
  • Partner Investment Management's biggest Q3 2015 reduction was BROADCOM CORP CL-A, cutting an estimated $1.13M.
  • Partner Investment Management fully exited Elevance Health in Q3 2015, selling an estimated $1.61M.
  • Partner Investment Management's ten largest holdings make up 44% of its $66.2M portfolio in Q3 2015.
  • Partner Investment Management opened 26 new positions and closed 42 in Q3 2015.
  • Partner Investment Management's portfolio value fell 7% quarter-over-quarter to $66.2M.

Based on Partner Investment Management's 13F filing for Q3 2015, filed 16 Nov 2015.